控制的低密度脂蛋白胆固醇减弱了皮肤穿透冠状动脉干预后由高脂蛋白介导的心血管风险 ()
Ahmed K Mahmoud1, Kamal Awad, Juan M Farina
1Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona, USA.
Coronary artery disease
|January 8, 2025
概括
最佳的低密度脂蛋白胆固醇 (LDL-C) 控制可能会在皮肤冠状动脉干预 (PCI) 后的患者中抵消高脂蛋白[Lp[a]的心血管风险. 这项研究发现,当LDL-C的管理良好时,没有增加主要不良心血管事件的风险或升高Lp的死亡率.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 预防医学 预防医学
背景情况:
- 脂蛋白 (Lp) 是已知的心血管疾病 (CVD) 的因果风险因素.
- 优化低密度脂蛋白胆固醇 (LDL-C) 控制对高Lp(a患者心血管疾病风险的影响,特别是在二次预防中,仍然不清楚.
研究的目的:
- 调查是否达到目标LDL-C水平 (<70 mg/dl) 减轻了与皮肤穿透冠状动脉干预 (PCI) 患者的升高Lp (a) 相关的心血管风险.
主要方法:
- 在2006年至2017年期间,对接受PCI并达到目标LDL-C水平 (<70 mg/dl) 的成年患者进行了回顾性分析.
- 用卡普兰-梅尔曲线和多变量考克斯回归来比较Lp (a) ≥50 mg/dl和Lp (a) <50 mg/dl的患者之间主要心血管不良事件 (MACE) 和全因死亡率.
主要成果:
- 这项研究包括878名患者 (29.7%的Lp(a) ≥50 mg/dl).
- 在高和正常的Lp (a) 组之间没有观察到MACE (P=0.91) 或所有原因死亡率 (P=0.26) 的生存概率的显著差异.
- 多变量分析显示,升高的Lp(a) 与MACE (HR: 1.07) 或所有原因死亡率 (HR: 0.98) 之间没有显著的关联.
结论:
- 在接受PCI且LDL-C控制良好 (<70 mg/dl) 的患者中,升高的Lp (≥50 mg/dl) 与MACE或全因死亡风险增加没有显著关联.
- 在这种高风险人群中,最佳的LDL-C管理似乎可以减轻Lp的益动脉动脉效应.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
529
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
529
Cholesterol: Significance and Regulation
500
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
500
Blood Studies for Cardiovascular System III: Serum Lipid Profile
130
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
130
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
452
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
452
Inflammation
52.5K
Overview
52.5K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465


